As a leading research-driven pharmaceutical and biotechnology company, Laurus Labs aims to improve the quality of life for millions around the world

We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We work with all the top 10 generic pharmaceutical companies in the world. We sell our APIs in 56 countries. Our major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.

Continuous innovation is the lifeblood of our business. Therefore, we undertake dedicated R&D in areas that have significant growth potential. We filed 296 patents in which we own 155 patents. We have commercialised 60+ products since inception across three distinct business units: Generics API, Generics FDF and Synthesis.

As a company, we conduct our business with utmost transparency and integrity. This helps us attract the best talent and win the trust of our stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.

Annual Report

We are making great progress on our strategic goals. See our latest annual report.


Discover more about Laurus Labs

We are a science-led company at our core. We push back the frontiers of science to serve the needs of humanity. Our state-of-the-art research labs enable us to produce new cures to some of the most challenging diseases. With our manufacturing facilities, we cracked the code of creating high-quality and affordable medicines. Our facilities have been certified and approved by WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM. Our strong R&D and API manufacturing capabilities are enabling us to grow rapidly. We are also one of the most-admired companies to work for in the pharmaceutical and biotechnology sector.



Incorporated Laurus Ingredients Pvt. Ltd. A Wholly Owned step down subsidiary of Laurus Synthesis Pvt. Ltd.
Acquisition of 72.55% stake in Richcore Life Sciences Pvt Ltd (Laurus Bio)


Incorporated Laurus Synthesis Pvt. Ltd
Acquired assets of an API Unit in Vizag
Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited


Unit 6 – EIR Received from USFDA
Entered into Strategic partnership with Global Fund for 3.5 years.
Executed a major tender order and delivered ahead of schedule
Executed highest on-time delivery in FDF orders.
Maiden EIR received for Unit 4


Crossed INR 20 billion of revenue. Commenced commercial operations from Unit 4.
Incorporated a subsidiary in Germany.
Unit 2-Formulations, inspected by USFDA with Zero 483 observations.
Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.
Certified as Great Place to Work for the year 2018.


Successful USFDA inspection of Unit 1, 2 & 3 API manufacturing facilities with no critical observations. (Unit 2 has no 483 observations)
Successful WHO inspection of Units 1, 2 & 3
Successful BGV Hamburg (German Regulatory Authority) inspection of Unit 2 (FDF) with no critical or major observations


Successful USFDA inspection of the kilo-lab facility at our R&D Centre
Received approval from BfArM Germany for Unit 2 at Vishakhapatnam
Crossed INR 15 billion in revenues
Filed first ANDA with the USFDA and first dossier with the WHO


Commenced commercial operations at Unit 3, Visakhapatnam
Acquired 27% stake in Sriam Labs Private Limited, Hyderabad
Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites


Acquired 135 acres in Visakhapatnam for expansion
Received an investment of INR 3000 million from Bluewater
Commenced construction of Unit 2
Incorporated Laurus Inc. in Delaware, US as a wholly-owned subsidiary


Crossed INR 10 billion in revenues
Received WHO approval for Unit-I


Secured investment of INR 490 million from FIL Capital Management and FIP through primary investment and
Secondary acquisition of Aptuit’s majority stake along with additional investments by one of our promoters


Received USFDA and KFDA certification for our R&D Centre
Received KFDA certification for Unit 1


Received USFDA, TGA and UK MHRA certification for the Unit 1, Vishakhapatnam


DSIR recognised our R&D Centre
Commercialised four nutritional fine chemicals
Launched first product in Europe
Entered into a license agreement with an international organisation and a multinational company to manufacture and sell our products in the ARV segment


Filed our first-ever Drug Master File
Commenced operations at Unit-I
Supplied company’s first product to the US


Set up API manufacturing facility Unit-I at Visakhapatnam
Secured investment from Aptuit Singapore of INR 1.02 billion
Executed manufacturing and services agreements with three multinational companies
Commenced operations at our R&D Centre


Set up our R&D Centre at IKP, Knowledge Park, Hyderabad
Signed a term sheet with a leading Indian pharmaceutical company for oncology APIs
Filed our first patent application


Our key indices


State-of-the-art R & D labs in India and the US


APIs manufactured at 8 manufacturing facilities


Million in annual revenues in FY20


Research scientists out of a total workforce of over 4000


Customers across 56 countries


Patents filed and 155 patents granted


Million liters of reactor capacity


Manufacturing Facilities